Growth through CGM MTd Group’s launch of Continuous Glucose Monitoring Systems and recent tender wins in Italy indicate a broader push into diabetes care tech. This presents cross-sell opportunities for HTL-STREFA safety lancets, pen needles, and immunization products to support CGM-related diabetes management workflows and device integration.

Expanded Capacity Strategic integration with Ypsomed’s pen needle operations and European production expansion increasing capacity to over 2.5 billion pen needles signals reliable supply and potential for large-volume contracts, enabling sales pitches centered on scalable procurement for distributors and clinics.

Broad Product Footprint HTL-STREFA’s portfolio under Droplet and DropSafe – including safety lancets, safety pen needles, insulin syringes, and immunization products – allows bundled procurement discussions with healthcare providers seeking comprehensive sharps safety solutions across diabetes and vaccination programs.

Innovation Recognition Recognition for the G34 pen needle as an industry-leading device highlights a credible innovation track record, which can be leveraged in sales narratives to justify price positioning, differentiate offerings, and secure partnerships with hospitals and clinics focused on best-in-class devices.

Global Footprint With production facilities in Europe and distribution in Europe and the USA, HTL-STREFA offers geographic reach suitable for multinational distributors and PE-backed medical suppliers seeking diversified supply chains and regional onboarding capabilities for new markets.